Citadel Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,300
| Closed | -$11.7K | – | 15476 |
|
|
2023
Q2 | $11.7K | Sell |
5,300
-12,900
| -71% | -$26.8K | ﹤0.01% | 13122 |
|
|
2023
Q1 | $46.2K | Buy |
18,200
+9,500
| +109% | +$18.8K | ﹤0.01% | 12258 |
|
|
2022
Q4 | $16.3K | Sell |
8,700
-5,700
| -40% | -$14.2K | ﹤0.01% | 13287 |
|
|
2022
Q3 | $37K | Sell |
14,400
-5,200
| -27% | -$12.9K | ﹤0.01% | 11802 |
|
|
2022
Q2 | $38K | Buy |
+19,600
| New | +$42.8K | ﹤0.01% | 12107 |
|
|
2022
Q1 | – | Sell |
-15,000
| Closed | -$67K | – | 14957 |
|
|
2021
Q4 | $67K | Buy |
15,000
+1,600
| +12% | +$7.59K | ﹤0.01% | 13077 |
|
|
2021
Q3 | $65K | Sell |
13,400
-14,700
| -52% | -$81K | ﹤0.01% | 13215 |
|
|
2021
Q2 | $192K | Sell |
28,100
-400
| -1% | -$3.23K | ﹤0.01% | 12208 |
|
|
2021
Q1 | $201K | Sell |
28,500
-5,900
| -17% | -$42.5K | ﹤0.01% | 11698 |
|
|
2020
Q4 | $215K | Buy |
34,400
+8,700
| +34% | +$51.2K | ﹤0.01% | 9632 |
|
|
2020
Q3 | $139K | Buy |
25,700
+7,600
| +42% | +$37.6K | ﹤0.01% | 9054 |
|
|
2020
Q2 | $94K | Buy |
+18,100
| New | +$80.4K | ﹤0.01% | 9025 |
|
|
2020
Q1 | – | Sell |
-23,100
| Closed | -$93K | – | 10372 |
|
|
2019
Q4 | $93K | Buy |
23,100
+2,700
| +13% | +$9.37K | ﹤0.01% | 8571 |
|
|
2019
Q3 | $88K | Buy |
+20,400
| New | +$81.6K | ﹤0.01% | 8541 |
|
|
2019
Q1 | – | Sell |
-24,900
| Closed | -$128K | – | 10058 |
|
|
2018
Q4 | $128K | Buy |
24,900
+6,600
| +36% | +$50.1K | ﹤0.01% | 8138 |
|
|
2018
Q3 | $178K | Sell |
18,300
-8,400
| -31% | -$84.7K | ﹤0.01% | 8308 |
|
|
2018
Q2 | $272K | Buy |
+26,700
| New | +$302K | ﹤0.01% | 7372 |
|
|
2017
Q4 | – | Sell |
-12,600
| Closed | -$316K | – | 8575 |
|
|
2017
Q3 | $316K | Sell |
12,600
-5,300
| -30% | -$123K | ﹤0.01% | 5991 |
|
|
2017
Q2 | $431K | Sell |
17,900
-23,200
| -56% | -$513K | ﹤0.01% | 5329 |
|
|
2017
Q1 | $791K | Buy |
+41,100
| New | +$648K | ﹤0.01% | 4353 |
|
Citadel Advisors's PRTK Position: Q1 2023 in Review
Citadel Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 203,159 shares — an estimated $401K sold.
Citadel Advisors first reported a position in PRTK in Q2 2015 and held it in 24 quarters. The position peaked at $2.86M in Q2 2018. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.
- Citadel Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 203,159 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $401K.
- Citadel Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's Paratek Pharmaceuticals, Inc. position peaked at $2.86M in Q2 2018.
- 63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.